Viltolarsen

DRUG6 trials

Sponsors

Ns Pharma Inc., NS Pharma, Inc.

Conditions

DMDDuchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)Muscular Dystrophy, Duchenne

Phase 2

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

CompletedNCT04956289

NS Pharma, Inc.Duchenne Muscular Dystrophy

Start: 2021-07-01End: 2023-07-13Updated: 2024-08-20

Phase 3

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

CompletedNCT04060199

NS Pharma, Inc.Duchenne Muscular Dystrophy

Start: 2020-04-14End: 2023-10-19Updated: 2024-12-11

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Active, not recruitingNCT04768062

NS Pharma, Inc.Duchenne Muscular Dystrophy

Start: 2021-04-13End: 2025-11-30Updated: 2024-02-14

A Phase 3, Multi-Center, Open Label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)

CompletedCTIS2023-507146-91-00

Ns Pharma Inc.Duchenne Muscular Dystrophy (DMD)

Start: 2021-06-07End: 2025-01-16Target: 21Updated: 2025-06-18

Phase 4

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Active, not recruitingNCT04687020

NS Pharma, Inc.Duchenne Muscular Dystrophy

Start: 2021-06-10End: 2032-10-31Updated: 2022-10-19

Unknown Phase

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

NS Pharma, Inc.DMD, Muscular Dystrophy, Duchenne

Updated: 2020-08-18

Related Papers

Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy.

2024-10-083 citations

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy

Journal of Neuromuscular Diseases2022-05-2455 citations